Same or different—that’s a big question rattling around the immuno-oncology field, where PD-1 and PD-L1 checkpoint inhibitors have put up differing results in clinical trials.
The assessment from Sanofi? The PD-1 drugs themselves are essentially equal. It’s the trial designs that make them look different, Joanne Lager, head of oncology development, said in an interview Wednesday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,